Zealand Pharma A/S
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Zealand Pharma A/S
Although SRF813 isn’t likely to reach the clinic until 2021, GSK likes cell therapy’s monotherapy and combination potential. Lilly bids $880m to acquire neurodegenerative cell therapy firm Prevail.
Having just entered into drug discovery partnerships with Surface Oncology and Adrestia, GSK is paying £34m upfront to team up with Sosei Heptares to evaluate treatments for gastrointestinal immune disorders.
Zealand has been hit by an unexpected Phase III failure for its glucagon analog product dasiglucagon in congenital hyperinsulinism, but all may not be lost for the indication.
Plus deals involving Takeda/OrigiMed, Amcure/Hinova, AUM/Newsoara, Taiho/Lung Therapeutics, 3D Medicines/Aravive, HitGen/Baiyunshan, Dong-A/Jiangsu Hengrui, and Crescita/Juyou.
- Other Names / Subsidiaries
- Encycle Therapeutics, Inc.
- Valeritas Holdings, Inc.